AUTHORS: SM Laws, RM Clarnette, K Taddei, G Martins, A Paton, J Hallmayer, OP Almeida, DM Groth, SE Gandy, H Frstl and RN Martins
Sir James McCusker Alzheimer's Disease Research Unit, Department of Surgery, University of Western Australia, Hollywood Private Hospital, Perth, Western Australia; Department of Psychiatry and Behavioural Science, Stanford University, Palo Alto, CA, USA; Department of Psychiatry and Behavioural Science, University of Western Australia, QE11 Medical Centre, Perth, Western Australia; School of Biomedical Science, Curtin University of Technology, Bentley, Western Australia; Alzheimer Research Program, New York University, NS Kline Institute, Orangeburg, New York, USA; Department of Psychiatry and Psychotherapy, Technical University of Munich, Munich, Germany.
Rational approaches to drug discovery for Alzheimer's disease are moving rapidly worldwide. Unfortunately, "prevention" is much more likely to be a successful strategy, rather than trying to re-create a severely damaged, demented brain. Genetic markers such as those studied by Martins and colleagues at the McCusker Alzheimer Foundation, University of Western Australia and Hollywood Private Hospital hold promise for guiding clinical trials: these markers may allow us to winnow down the general population to a more manageable pool of individuals with relatively higher risk for Alzheimer's. In this project, Martins and colleagues developed a set of tools for identifying such enriched populations. This work may impact on future clinical trials of anti-Alzheimer drugs.
'"/>
Contact: Frank Sissingh
molecularpsychiatry@mednet.ucla.edu
310-206-6739
Molecular Psychiatry
3-Sep-2002